logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

How Good Is Xoma's Good News?

XOMA Establishes Proof-of-Concept for 358 in Congenital Hyperinsulinism and Hypoglycemia Post-Bariatric Surgery Congenital Hyperinsulinism Phase 2 study completed and multi-dose study protocol approved in the United Kingdom. Xoma initiates multi-dose study in hypoglycemic Post-Bariatric Surgery patients The N E W...

Read More

February 4, 2017

0

Gilead Sciences: A Case Study

Gilead Sciences (GILD) was subjected to what we believe is an exaggerated stock selloff following the announcement of its 2016 financial reports, which comprised its projections made for 2017. Investors seemed to have focused only on the HCV sales’ revenues...

Read More

February 9, 2017

0

AstraZeneca: Advancing and improving Stage III lung cancer treatments

Stage III ( locally-advanced ) NSCLC is commonly divided into three sub-categories: IIIA, IIIB and IIIC, defined by how much the cancer has spread locally and the possibility of surgery. The difference between Stage III and Stage IV disease (cancer...

Read More

September 26, 2018

0

Why Agenus and Incyte Are Both Winners Amending Their Original Agreement

Incyte (INCY) and Agenus (AGEN) announced an amendment of the License, Development and Commercialization Agreement that was originally agreed upon by the two firms on January 9, 2015. The amended converts the ongoing antibodies targeting GITR and OX40 programs from...

Read More

February 14, 2017

0

Seattle Genetics and Takeda Pharmaceutical Limited announced a successful trial on mature T-Cell lymphoma

Seattle Genetics (SGEN) and  Takeda Pharmaceutical Limited ( TKPYY) announced results from Phase 3 ECHELON-2 clinical trial evaluating Adcetris as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-expressing peripheral T-cell lymphoma (PTCL), known also as mature...

Read More

October 1, 2018

0

Seattle Genetics and Pieris Pharmaceuticals: A Collaboration to Improve Cancer Immunotherapy

Seattle Genetics and Pieris pharmaceutical Collaboration Agreement Pieris Pharmaceuticals (PIRS)  and  Seattle Genetics (SGEN)  signed a multi-program immuno-oncology collaboration agreement intended to evaluate novel bi-specific immuno-oncology agents. These agents would combine  Pieris’ Anticalin proteins drugs  with Seattle Genetics’ targeted antibodies...

Read More

February 15, 2018

0

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

Portola Pharmaceuticals and the CHMP’s Oral Explanations  for Andexanet Alfa and Betrixaban Portola (PTLA)   announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated a  positive trend vote  on the Marketing Authorization Application (MAA)...

Read More

February 21, 2018

0

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

Alnylam (ALNY)  announced that Sanofi Genzyme declined its opt-in for the development and commercialization of the RNAi product  lumasiran , an investigational RNAi therapeutic for the treatment of  Primary Hyperoxaluria Type 1 (PH1).  Based on this decision, Alnylam intends to...

Read More

March 13, 2018

0

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

FERTILITY Fertility is what guarantees the presence of humans on the planet Earth. The reproductive system in men and women are the engines of fertility that creates living beings. These important engines get disturbed in some people, which represents a...

Read More

February 27, 2018

0

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

Regeneron’s (REGN)   pipeline products have still a lot of good news to announce. The latest is about its product Dupixant (dupilumab) which has already been FDA approved for atopic dermatitis. Now, there are reasons to believe that this drug...

Read More

March 6, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 44
  • 45
  • 46
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy